Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia

Blood

Volumn 122, Issue 16, 2013, Pages 2893-2902

  Casari, Caterina ^a,b   Du, Vivian ^c   Wu, Ya Ping ^c   Kauskot, Alexandre ^a,b   De Groot, Philip G ^c   Christophe, Olivier D ^a,b   Denis, Cécile V ^a,b   De Laat, Bas ^c   Lenting, Peter J ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BOTROCETIN; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CELL ACTIVATION; CLEARANCE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOCYTOSIS; FEMALE; HALF LIFE TIME; IMMUNOFLUORESCENCE TEST; INTERNALIZATION; KUPFFER CELL; LIVER; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; SCANNING ELECTRON MICROSCOPY; SHEAR STRESS; SPLEEN; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; THROMBOCYTE MEMBRANE; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE; ANIMAL; BLOOD; C57BL MOUSE; CYTOLOGY; HEMOSTASIS; METABOLISM; PATHOPHYSIOLOGY; PERFUSION; PHAGOCYTOSIS;

ANIMALS; BLOOD PLATELETS; FEMALE; HEMOSTASIS; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; PERFUSION; PHAGOCYTOSIS; SPLEEN; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND FACTOR;

EID: 84888239369     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-493312     Document Type: Article

References (37)

1. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res. 2007; 120(suppl 1):S5-S9.
2. Sadler JE, Budde U, Eikenboom JC, et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
3. Federici AB, Canciani MT. Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease. Haematologica. 2009;94(5):610-615.
4. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113(3):526-534.
5. Nurden P, Debili N, Vainchenker W, et al. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood. 2006;108(8): 2587-2595.
6. Nurden AT, Federici AB, Nurden P. Altered megakaryocytopoiesis in von Willebrand type 2B disease. J Thromb Haemost. 2009;7(suppl 1): 277-281.
7. Nurden P, Gobbi G, Nurden A, et al. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood. 2010;115(13):2649-2656.
8. Saba HI, Saba SR, Dent J, Ruggeri ZM, Zimmerman TS. Type IIB Tampa: a variant of von Willebrand disease with chronic thrombocytopenia, circulating platelet aggregates, and spontaneous platelet aggregation. Blood. 1985;66(2):282-286.
9. Rick ME, Williams SB, Sacher RA, McKeown LP. Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand’s disease. Blood. 1987;69(3):786-789.
10. Mathew P, Greist A, Maahs JA, Lichtenberg EC, Shapiro AD. Type 2B vWD: the varied clinical manifestations in two kindreds. Haemophilia. 2003;9(1):137-144.
11. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood. 2009; 113(21):5049-5057.
12. Rayes J, Hollestelle MJ, Legendre P, et al. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood. 2010;115(23): 4870-4877.
13. Golder M, Pruss CM, Hegadorn C, et al. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions. Blood. 2010;115(23):4862-4869.
14. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA. 1998;95(16):9524-9529.
15. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem. 2004;279(13):12102-12109.
16. Marx I, Christophe OD, Lenting PJ, et al. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood. 2008;112(3):603-609.
17. Berger G, Hartwell DW, Wagner DD. P-Selectin and platelet clearance. Blood. 1998;92(11): 4446-4452.
18. van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood. 2008;112(5):1704-1712.
19. Rastegarlari G, Pegon JN, Casari C, et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood. 2012;119(9): 2126-2134.
20. Castro-Núñez L, Dienava-Verdoold I, Herczenik E, Mertens K, Meijer AB. Shear stress is required for the endocytic uptake of the factor VIII-von Willebrand factor complex by macrophages. J Thromb Haemost. 2012;10(9):1929-1937.
21. Nurden P, Chretien F, Poujol C, Winckler J, Borel-Derlon A, Nurden A. Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease. Br J Haematol. 2000;110(3): 704-714.
22. van Rooijen N. Liposome-mediated elimination of macrophages. Res Immunol. 1992;143(2): 215-219.
23. Mannucci PM. How I treat patients with von Willebrand disease. Blood. 2001;97(7): 1915-1919.
24. McKeown LP, Connaghan G, Wilson O, Hansmann K, Merryman P, Gralnick HR. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand’s disease. Am J Hematol. 1996;51(2):158-163.
25. Mauz-Körholz C, Budde U, Kruck H, Körholz D, Göbel U. Management of severe chronic thrombocytopenia in von Willebrand’s disease type 2B. Arch Dis Child. 1998;78(3):257-260.
26. Schneppenheim R. The pathophysiology of von Willebrand disease: therapeutic implications. Thromb Res. 2011;128(suppl 1):S3-S7.
27. Jilma-Stohlawetz P, Knöbl P, Gilbert JC, Jilma B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost. 2012;108(2):284-290.
28. Alves-Rosa F, Stanganelli C, Cabrera J, van Rooijen N, Palermo MS, Isturiz MA. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood. 2000;96(8):2834-2840.
29. Gordy C, Pua H, Sempowski GD, He YW. Regulation of steady-state neutrophil homeostasis by macrophages. Blood. 2011; 117(2):618-629.
30. Miyake Y, Asano K, Kaise H, Uemura M, Nakayama M, Tanaka M. Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigens. J Clin Invest. 2007; 117(8):2268-2278.
31. Neiman JC, Mant MJ, Shnitka TK. Phagocytosis of platelets by Kupffer cells in immune thrombocytopenia. Arch Pathol Lab Med. 1987; 111(6):563-565.
32. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell. 2003;112(1):87-97.
33. Josefsson EC, Gebhard HH, Stossel TP, Hartwig JH, Hoffmeister KM. The macrophage alphaMbeta2 integrin alphaM lectin domain mediates the phagocytosis of chilled platelets. J Biol Chem. 2005;280(18):18025-18032.
34. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 2005; 106(9):3035-3042.
35. de Mast Q, Groot E, Lenting PJ, et al. Thrombocytopenia and release of activated von Willebrand factor during early Plasmodium falciparum malaria. J Infect Dis. 2007;196(4): 622-628.
36. Jaff MS, McKenna D, McCann SR. Platelet phagocytosis: a probable mechanism of thrombocytopenia in Plasmodium falciparum infection. J Clin Pathol. 1985;38(11):1318-1319.
37. Kadri A, Noinuddin M, de Leeuw NK. Phagocytosis of blood cells by splenic macrophages in thrombotic thrombocytopenic purpura. Ann Intern Med. 1975;82(6):799-802.